A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer

Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.

Trial Details

NCT ID
NCT07241767
Phase
PHASE2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin
  • FH-006 ; SHR-1316 ; BP102
  • FH-006; SHR-1316 ; SHR-8068
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Age range: 18-75 years old (including both ends), gender is not limited.
  • Subjects with locally advanced or metastatic non-small cell lung cancer confirmed by histology or cytology as unsuitable for radical surgery or rad…
  • ECOG score is 0 or 1
  • Expected survival period ≥ 12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →